Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular...

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Cancer vasculature is characterized by immaturity, disorganization, and hyperpermeability, making it a viable target for anti-cancer therapies.
• Vascular disrupting agents (VDAs) function by binding and depolymerizing tubulin proteins, leading to rapid shutdown of tumor vasculature and subsequent cancer necrosis.
• Existing VDAs face challenges including incomplete anti-cancer effects and dose-dependent toxicity.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a novel VDA, C118P, administered via transarterial infusion in a VX2 liver tumor rabbit model.
• To assess if transarterial administration of a reduced dose of C118P can overcome the limitations of conventional VDA therapy.

Main Methods:

• VX2 liver tumors were implanted in rabbits.
• A novel VDA, C118P, was administered at a dose of 5 mg/kg via transarterial infusion.
• Therapeutic efficacy was assessed using in vivo digital subtraction arteriogram (DSA), magnetic resonance imaging (MRI), ex vivo microangiogram, and histopathology.

Main Results:

• A single transarterial dose of C118P at 5 mg/kg resulted in nearly complete tumor necrosis.
• The outcome was corroborated by multiple imaging modalities and histopathological analysis.
• This administration route utilized half the dose typically administered intravenously.

Conclusions:

• Transarterial administration of the novel VDA C118P shows significant potential for treating solid cancers, achieving substantial tumor necrosis.
• This approach may offer an effective strategy to overcome the dose-dependent toxicity and incomplete efficacy associated with traditional VDA therapies.
• Further comprehensive studies are warranted to explore the full potential of transarterial VDAs in cancer management, both as monotherapy and in combination treatments.